

III. 研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
降幡知巳、 坪田昭人、 千葉寛	リバビリン輸送を担う核酸トランスポーターとそのC型肝炎治療における役割	楠原洋之	医学のあゆみ「トランスポーターと疾患研究の最前線」	医歯薬出版株式会社	東京	2013	113 - 119

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Furihata T, Mizuguchi M, Suzuki Y, Matsumoto S, Kobayashi K, Chiba K.	Identification of primary equilibrative nucleoside transporter 1 mRNA isoforms resulting from alternative promoter usage in human hepatocytes.	Drug Metab Pharmacokine		In press.	2014
Furihata T, Kishida S, Sugiura H, Kamiichi A, Iikura M, Chiba K.	Functional analysis of purine nucleoside phosphorylase as a key enzyme in ribavirin metabolism.	Drug Metab Pharmacokine	29 (2)	211-214	2014
Chiba K.	Perspective of humanized mouse models for assessing PK/PD and toxic profile of drug candidates in preclinical study.	Drug Metab Pharmacokine	29 (1)	1-2	2014
Tsubota A, Mogushi K, Aizaki H, Miyaguchi K, Nagatsuma K, Matsudaira H, Kushida T, Furihata T, Tanaka H, Matsuura T.	Involvement of MAP3K8 and miR-17-5p in Poor Virologic Response to Interferon-Based Combination Therapy for Chronic Hepatitis C.	PLoS One	9 (5)	e97078	2014
Shimada N, Tsubota A, Atsukawa M, Abe H, Ide T, Takaguchi K, Chuganji Y, Toyoda H, Yoshizawa K, Ika M, Sato Y, Kato K, Kumada T, Sakamoto C, Aizawa Y, Sata M.	A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.	Hepatol Res.		In press.	2014

Atsukawa M*, Tsubota A*, Shimada N, Kondo C, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Narahara Y, Osada Y, Yamaguchi H, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C.	Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C.	Eur J Gastroenterol Hepatol.	In press.		2014
Atsukawa M*, Tsubota A*, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Narahara Y, Iwakiri K, Nakatsuka K, Kawamoto C, Sakamoto C.	Serum 25-hydroxy- vitamin D3 levels affect treatment outcome in pegylated-interferon/ ribavirin combination therapy for compensated cirrhotic patients with HCV genotype 1b and high viral load.	Hepatol Res.	In press.		2014
Atsukawa M*, Tsubota A*, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C.	Efficacy of alfacalcidol on PEG-IFN/ribavirin combination therapy for elderly patients with chronic hepatitis C: a pilot study.	Hepat Mon.	13	e14872	2013
Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto, Kan Chiba.	Sustained and rapid virological responses in hepatitis C clinical trials	Clinical Investigatio	3 (11)	1083-1093	2013
Shimada N, Toyoda H, Tsubota A, Ide T, Takaguchi K, Kato K, Kondoh M, Matsuyama K, Kumada T, Sata M.	Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.	J Gastroenterol.	In press.		2014
Shimada N*, Tsubota A*, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y.	-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype.	J Med Virol.	86	461-72	2014

Tsubota A*, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y.	Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.	J Gastroenterol Hepatol.	29:	144-50	2014;
Aizawa Y, Shimada N, Abe H, Seki N, Aida Y, Ishiguro H, Ika M, Kato K, Tsubota A.	Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection.	Hepat Mon.	13	e8988	2013
Yoshizawa K, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N, Tsubota A, Aizawa Y.	Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.	J Med Virol	85	1180-90	2013
Ito K, Yotsuyanagi H, Yatsunami H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group (Appendix; Tsubota A)	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.	Hepatology	59	89-97	2014
Nagatsuma K, Hano H, Murakami K, Shindo D, Matsumoto Y, Mitobe J, Tanaka K, Saito M, Maehashi H, Owada M, Ikegami M, Tsubota A, Ohkusa T, Aizawa Y, Takagi I, Tajiri H, Matsuura T.	Hepatic stellate cells that coexpress LRAT and CRBP-1 partially contribute to portal fibrogenesis in patients with human viral hepatitis.	Liver Int	34	243-52	2014
Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y.	New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.	J Med Virol	85	1523-33	2013

Kanda T, Kato K, Tsubota A, Takada N, Nishino T, Mikami S, Miyamura T, Maruoka D, Wu S, Nakamoto S, Arai M, Fujiwara K, Imazeki F, Yokosuka O.	Platelet count and sustained virological response in hepatitis C treatment.	World Hepatol.	J5	182-8	2013
Kanda T, Nakamoto S, Nishino T, Takada N, Tsubota A, Kato K, Miyamura T, Maruoka D, Wu S, Tanaka T, Arai M, Mikami S, Fujiwara K, Imazeki F, Yokosuka O.	Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.	Int J Med Sci.	10	43-9	2013
Itokawa N, Atsukawa M*, Tsubota A*, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.	Lead-in treatment with interferon- /ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.	J Gastroenterol Hepatol.	28	443-9	2013
Atsukawa M*, Tsubota A*, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Kanazawa H, Sakamoto C.	Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.	J Gastroenterol Hepatol.	28	51-6	2013

